心源性休克患者的肝素诱导性血小板减少症
这项回顾性双中心研究纳入2010年1月至2022年11月慕尼黑Ludwig-Maximilians大学医院和波恩大学医院心脏ICU的2808例确诊心源性休克且疑似HIT的成人患者。疑似HIT者中抗血小板因子4/肝素筛查抗体阳性159例(5.7%),功能试验确诊HIT 57例,患病率2.0%,筛查抗体阳性预测值35.8%。排除HIT与确诊HIT患者的住院死亡率(58.8% vs 57.9%,p>0.999)、1个月死亡率(47.1% vs 43.9%,p=0.781)、12个月死亡率(58.8% vs 59.6%,p>0.999)均相似,幸存者神经结局(CPC 1:8.8% vs 8.8%,p>0.999;CPC 2:7.8% vs 12.3%,p=0.485)也无显著差异。作者认为HIT是心源性休克患者使用普通肝素治疗中的罕见并发症,未伴随死亡率增加。
要点
- 2808例心源性休克患者中,抗血小板因子4/肝素筛查抗体阳性159例(5.7%),功能试验确诊HIT 57例,患病率2.0%。
- 抗血小板因子4/肝素筛查抗体阳性预测值为35.8%,提示筛查抗体阳性不能直接诊断HIT。
- 排除HIT与确诊HIT患者住院死亡率分别为58.8%与57.9%(p>0.999),1个月死亡率47.1%与43.9%(p=0.781),12个月死亡率58.8%与59.6%(p>0.999)。
- 幸存者神经结局CPC 1为8.8% vs 8.8%(p>0.999),CPC 2为7.8% vs 12.3%(p=0.485),组间无显著差异。
- 作者认为心源性休克患者使用普通肝素时HIT为罕见并发症,且未伴随死亡率增加。
适用人群与场景
- 2010年1月至2022年11月慕尼黑Ludwig-Maximilians大学医院和波恩大学医院心脏ICU收治的18岁及以上、确诊心源性休克且疑似HIT的成人患者。
研究设计与关键结果
- 回顾性双中心研究,纳入2808例确诊心源性休克且疑似HIT的成人患者,比较排除HIT与确诊HIT患者的基线特征、死亡率、神经及安全性结局。
- 疑似HIT者中抗血小板因子4/肝素筛查抗体阳性159/2808例(5.7%),功能试验确诊HIT 57/2808例(患病率2.0%),筛查抗体阳性预测值35.8%。
- 排除HIT与确诊HIT患者的住院总死亡率58.8% vs 57.9%(p>0.999),1个月死亡率47.1% vs 43.9%(p=0.781),12个月死亡率58.8% vs 59.6%(p>0.999)。
- 幸存者神经结局CPC 1为8.8% vs 8.8%(p>0.999),CPC 2为7.8% vs 12.3%(p=0.485)。
证据类型、等级与局限
- 证据类型:回顾性双中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为HIT是心源性休克患者使用普通肝素治疗中的罕见并发症,且未伴随死亡率增加;HIT确诊与幸存者更差的神经结局无关。
- 作者建议未来研究应致力于开发更精确、标准化且具成本效益的HIT诊断策略并预防并发症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Cardiogenic shock (CS) is associated with high mortality. Patients treated for CS mostly require heparin therapy, which may be associated with complications such as heparin-induced thrombocytopenia (HIT). HIT represents a serious condition associated with platelet decline and increased hypercoagulability and remains a poorly researched field in intensive care medicine. Primary purpose of this study was to: 1) determine HIT prevalence in CS, 2) assess the performance of common diagnostic tests for the workup of HIT, and 3) compare outcomes in CS patients with excluded and confirmed HIT.
DESIGN: Retrospective dual-center study including adult patients 18 years old or older with diagnosed CS and suspected HIT from January 2010 to November 2022.
SETTING: Cardiac ICU at the Ludwig-Maximilians University hospital in Munich and the university hospital of Bonn.
PATIENTS AND INTERVENTIONS: In this retrospective analysis, adult patients with diagnosed CS and suspected HIT were included. Differences in baseline characteristics, mortality, neurologic and safety outcomes between patients with excluded and confirmed HIT were evaluated.
MEASUREMENTS AND MAIN RESULTS: In cases of suspected HIT, positive screening antibodies were detected in 159 of 2808 patients (5.7%). HIT was confirmed via positive functional assay in 57 of 2808 patients, corresponding to a prevalence rate of 2.0%. The positive predictive value for anti-platelet factor 4/heparin screening antibodies was 35.8%. Total in-hospital mortality (58.8% vs. 57.9%; p > 0.999), 1-month mortality (47.1% vs. 43.9%; p = 0.781), and 12-month mortality (58.8% vs. 59.6%; p > 0.999) were similar between patients with excluded and confirmed HIT, respectively. Furthermore, no significant difference in neurologic outcome among survivors was found between groups (Cerebral Performance Category [CPC] score 1: 8.8% vs. 8.8%; p > 0.999 and CPC 2: 7.8% vs. 12.3%; p = 0.485).
CONCLUSIONS: HIT was a rare complication in CS patients treated with unfractionated heparin and was not associated with increased mortality. Also, HIT confirmation was not associated with worse neurologic outcome in survivors. Future studies should aim at developing more precise, standardized, and cost-effective strategies to diagnose HIT and prevent complications.
参考来源
- Lüsebrink E, Lanz H, Binzenhöfer L, et al. Heparin-Induced Thrombocytopenia in Patients Suffering Cardiogenic Shock. Crit Care Explor. 2024. PMID: 39042702. doi:10.1097/CCE.0000000000001117
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。